ClinicalTrials.gg

Program

cemdisiran

Also written as “Cemdisiran”, “Pozelimab + Cemdisiran” and “ALN-CC5”.

Its studies are mostly in Hemoglobinuria, Paroxysmal · Geographic Atrophy · Myasthenia Gravis · Glomerulonephritis, IGA · Atypical Hemolytic Uremic Syndrome, led by 2 companies.

Furthest: phase 3, since Sep 27, 202110 company-led studies, 4 open or runningNext primary completion: Jul 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals74 open or runningphase 3since Sep 27, 2021Oct 21, 2020Jul 31, 2028phase 3 · NCT06541704
Alnylam Pharmaceuticals30 open or runningphase 2since Jan 23, 2015Jan 23, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 23, 2015First study: phase 2 study in Hemoglobinuria, ParoxysmalNew to Alnylam PharmaceuticalsAlnylam Pharmaceuticals · NCT02352493 · 62 enrolled · Spain, United Kingdom
  2. Sep 25, 2017Phase 2 study in Atypical Hemolytic Uremic SyndromeAlnylam Pharmaceuticals · NCT03303313 · Bosnia and Herzegovina, Canada, Estonia and more
  3. Feb 13, 2019Phase 2 study in Glomerulonephritis, IGAAlnylam Pharmaceuticals · NCT03841448 · 31 enrolled · Canada, France, Malaysia and more
  4. Oct 21, 2020Regeneron Pharmaceuticals's first study: phase 1 study in HealthyNew to Regeneron PharmaceuticalsRegeneron Pharmaceuticals · NCT04601844 · 19 enrolled · Belgium
  5. Mar 19, 2021Phase 2 study in Hemoglobinuria, ParoxysmalRegeneron Pharmaceuticals · NCT04811716 · 24 enrolled · Hong Kong, Hungary, Korea, Republic of and more
  6. Apr 23, 2021Phase 2 study in Hemoglobinuria, ParoxysmalRegeneron Pharmaceuticals · NCT04888507 · 6 enrolled · United Kingdom
  7. Sep 27, 2021Phase 3 study in Myasthenia GravisRegeneron Pharmaceuticals · NCT05070858 · 288 enrolled · United States, Belgium, Brazil and more
  8. Feb 6, 2023Phase 3 study in Hemoglobinuria, ParoxysmalRegeneron Pharmaceuticals · NCT05744921 · 202 planned · Brazil, Canada, Colombia and more
  9. Aug 2, 2024Phase 3 study in Macular DegenerationRegeneron Pharmaceuticals · NCT06541704 · 975 planned · United States, Australia, Austria and more
  10. Aug 13, 2025Phase 3 study in Hemoglobinuria, ParoxysmalRegeneron Pharmaceuticals · NCT07154745 · 35 planned · Brazil, Canada, Italy and more

Ahead

  1. Jul 31, 2028Primary completion: phase 3 study in Macular DegenerationRegeneron Pharmaceuticals · NCT06541704
  2. Oct 10, 2028Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalRegeneron Pharmaceuticals · NCT05744921
  3. Jan 18, 2030Primary completion: phase 3 study in Hemoglobinuria, ParoxysmalRegeneron Pharmaceuticals · NCT07154745

TargetBeta

C5 →read by rule
“A proprietary formulation composed of small-interfering RNAs (siRNAs) directed against terminal complement component 5 (C5) of the complement pathway ”NCIt, by rule

Other programs on C5

ProgramCompanyFurthest phaseStudies
eculizumabruleAstraZenecaphase 438
ravulizumabruleAstraZenecaphase 435
pozelimabruleRegeneron Pharmaceuticalsphase 414
zilucoplanruleUCBphase 314
vilobelimabruleinflarx-gmbhphase 313
CrovalimabruleHoffmann-La Rochephase 310
ABBV-6628AbbViephase 21

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07154745Hemoglobinuria, Paroxysmal · Brazil, Canada, Italy and more3RecruitingRegeneron PharmaceuticalsJan 18, 203035
NCT06541704Macular Degeneration · United States, Australia, Austria and more3RecruitingRegeneron PharmaceuticalsJul 31, 2028975
NCT05744921Hemoglobinuria, Paroxysmal · Brazil, Canada, Colombia and more3RecruitingRegeneron PharmaceuticalsOct 10, 2028202
NCT05070858Myasthenia Gravis · United States, Belgium, Brazil and more3Active, not recruitingRegeneron PharmaceuticalsJul 8, 2025288
NCT04888507Hemoglobinuria, Paroxysmal · United Kingdom2CompletedRegeneron PharmaceuticalsMay 5, 20226
NCT04811716Hemoglobinuria, Paroxysmal · Hong Kong, Hungary, Korea, Republic of and more2CompletedRegeneron PharmaceuticalsOct 25, 202224
NCT04601844Healthy · Belgium1CompletedRegeneron PharmaceuticalsJul 23, 202119
NCT03841448Glomerulonephritis, IGA · Canada, France, Malaysia and more2TerminatedAlnylam PharmaceuticalsMar 17, 202231
NCT03303313Atypical Hemolytic Uremic Syndrome · Bosnia and Herzegovina, Canada, Estonia and more2WithdrawnAlnylam PharmaceuticalsSep 12, 20180
NCT02352493Hemoglobinuria, Paroxysmal · Spain, United Kingdom2CompletedAlnylam PharmaceuticalsApr 201662

How it is read

Names in the registry

  • “Cemdisiran”, 9 entries
  • “Pozelimab + Cemdisiran”, 1 entry
  • “ALN-CC5”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.